The present disclosure is directed to conjugates of a specific binding entity and an oligomer, i.e. [Specific Binding Entity]-[Oligomer].sub.n, wherein n is an integer ranging from 1 to 12, and where the Oligomer includes, in some embodiments, a PNA sequence having at least one substituent at a gamma carbon position. In some embodiments, the substituent at the gamma carbon position, e.g. an amino acid, a peptide, a miniPEG, or a polymer, includes at least one reporter moiety.

A composition and method of detecting an analyte in a sample using the composition, the composition including: a liquid that includes water; a plurality of first hollow glass bubbles in the liquid; a plurality of covalently attached first affinity groups that are covalently attached to at least some of the plurality of first hollow glass bubbles; and a plurality of first detector compound molecules not covalently bonded to the plurality of first hollow glass bubbles; wherein the first detector compound molecules include a first detectable group that is detected at a first wavelength; and wherein the first hollow glass bubbles have: a density of less than 0.60 gram/mole; a span of less than 1.0; and a plurality of covalently attached first affinity groups.

The invention generally relates to performing sandwich assays in droplets. In certain embodiments, the invention provides methods for detecting a target analyte that involve forming a compartmentalized portion of fluid including a portion of a sample suspected of containing a target analyte and a sample identifier, a first binding agent having a target identifier, and a second binding agent specific to the target analyte under conditions that produce a complex of the first and second binding agents with the target analyte, separating the complexes, and detecting the complexes, thereby detecting the target analyte.

The invention generally relates to performing sandwich assays in droplets. In certain embodiments, the invention provides methods for detecting a target analyte that involve forming a compartmentalized portion of fluid including a portion of a sample suspected of containing a target analyte and a sample identifier, a first binding agent having a target identifier, and a second binding agent specific to the target analyte under conditions that produce a complex of the first and second binding agents with the target analyte, separating the complexes, and detecting the complexes, thereby detecting the target analyte.

The disclosure is directed to conjugates, e.g. PNA conjugates, as well as methods of employing the conjugates for detecting one or more targets in a biological sample, e.g. a tissue sample.

Provided herein are compositions and methods useful for the analysis and authentication of polysaccharide-rich herbs, such as Dendrobium officinale, Radix Astragali, Radix Angelica Sinensis, and related herbal products.

In the field of Hepatitis B virus (HBV) detection, disclosed are a method for detecting HBcAg by means of using a double antibody sandwich method, and an antibody and kit for detecting HBcAg; also included is a monoclonal antibody that can be used in the immunological detection of HBcAg in a tissue or cell sample.

Antibodies which bind selectively to cardiac conduction system (CCS) cells, imaging and/or diagnostic reagents and compositions visualizing the CCS cells and therapeutic products and compositions comprising one or more of the antibodies. Methods for delivering therapeutic agents to the CCS cells. The disclosure further provides methods for visualizing the CCS cells in vivo in real time, including in a subject undergoing a cardiothoracic surgery or other cardiac intervention. Compositions and methods for isolation, purification, analyses and/or transplantation of the CCS cells, including pluripotent stem cell (hiPSC)-derived or human embryonic stem cell (hESC)-derived CCS cells.

The present disclosure relates to the development of novel immunoassays for the detection of SARS-CoV-2 or secreted spike protein (or fragments thereof) in saliva, nasal mucosal sample, throat samples, or nasopharyngeal samples.

An immunochromatography includes steps of mixing a specimen capable of containing an antigen and a modified particle, which is a particle modified with a substance having a specific affinity to the antigen, to obtain a mixture containing particle composite bodies; sedimenting the particle composite bodies in the mixture using a centrifuge; dissociating the sedimented particle composite bodies into the particles and the antigen by mixing the sedimented particle composite bodies with a dissociation solution, recovering an antigen-concentrated solution by sedimenting the dissociated particles using a centrifuge; neutralizing the antigen-concentrated solution using a neutralization solution; spreading particle composite bodies for labeling on an insoluble carrier having a reaction site, in a state where the particle composite bodies for labeling, which are composite bodies of the antigen in the neutralized antigen-concentrated solution and a modified particle for labeling, are formed; and capturing the particle composite bodies for labeling at the reaction site.